GlyTherix is pleased to announce the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams. Funds will be used to generate new preclinical models to evaluate the efficacy, biodistribution, and pharmacokinetics of our lead cancer immunotherapy antibody, Miltuximab®.
Recent installation of start-of-the-art PET-CT and SPECT-CT imaging systems at ANSTO will facilitate high-resolution small animal imaging of Miltuximab®.
The theranostic products produced and tested in this project will generate significant input for the design of our Phase Ib trial to ensure that safety and efficacy endpoints will be met with confidence.
Dr Brad Walsh, CEO GlyTherix, commented “We are extremely grateful to the NSW Government for their continued support of our important therapeutic program, particularly as we have a first-in-world radio-immunotherapy developed in NSW. Additionally, we are pleased that this strengthens our long collaboration with ANSTO who have partnered with us in developing this radioimmunotherapy. A win-win for NSW companies.”
More details about the TechVouchers program can be found at: